Meyka Pro banner
Eli Lilly and Company

Eli Lilly and Company (LLY) Stock Overview

Explore Eli Lilly and Company’s financial performance, market position, analyst ratings, and future outlook.

LLYNYSE
HealthcareDrug Manufacturers - General
$1231.58
$45.87(3.87%)
U.S. Market opens in 1h 35m

Eli Lilly and Company (LLY)

Meyka AI Score

Z

Key Financials

Market Cap1.2T
P/E Ratio41.13
EPS (TTM)$31.49
ROE0.93%
Fundamental Analysis

AI Price Forecasts

1 Month$1293.38
3 Months$1112.07
1 Year Target$1159.57

LLY Stock Analysis & Investment Overview (NYSE)

Our AI-powered analysis of Eli Lilly and Company (NYSE: LLY) gives investors deep insight into how the stock performs on the NYSE exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Eli Lilly and Company's NYSE-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of LLY on the NYSE shows an RSI of 60.56, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $1159.57 for the NYSE listing.

Key metrics behind Eli Lilly and Company's NYSE-traded stock include a P/E ratio of 41.13 and a market capitalization of 1.2T. Combined with our AI analysis, these give both institutional and retail investors a clear view of LLY on the NYSE.

Price Performance (NYSE: LLY)

1-Day Change
3.85%
5-Day Change
4.89%
1-Month Change
3.60%
3-Month Change
29.83%
6-Month Change
20.19%
Year-to-Date (YTD) Change
14.58%
1-Year Change
93.86%
3-Year Change
136.20%
5-Year Change
357.009%
All-Time (Max) Change
43722.44%

Contact Information

317 276 2000
Lilly Corporate Center, Indianapolis, IN, 46285

Company Facts

500,000 Employees
IPO DateJun 1, 1972
CountryUS
Actively Trading

Frequently Asked Questions